| 2026-04-23 |
详情>>
股本变动：
变动后总股本12074.33万股
变动原因 ▼▲
- 原因：
- Common Stock offered 16,129,033 shares by the company
|
| 2026-02-17 |
详情>>
业绩披露：
2026年一季报每股收益-0.38美元,归母净利润-2305.81万美元,同比去年增长-232.69%
|
| 2026-01-26 |
股东大会：
将于2026-03-10召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees, Faisal G. Sukthian, Yezan Haddadin and Kurt J. Hilzinger, to the Board of Directors as Class I Directors to hold office until the 2029 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2026.
3.A non-binding advisory vote on the compensation of Outlook Therapeutics, Inc.’s named executive officers.
4.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2026-01-01 |
复牌提示：
2025-12-31 16:10:00 停牌，复牌日期 2025-12-31 16:35:00
|
| 2025-12-19 |
详情>>
业绩披露：
2025年年报每股收益-1.79美元,归母净利润-6242.49万美元,同比去年增长17.17%
|
| 2025-08-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.6美元,归母净利润-4913.21万美元,同比去年增长39.39%
|
| 2025-05-15 |
详情>>
业绩披露：
2025年中报每股收益-1.05美元,归母净利润-2897.96万美元,同比去年增长76.90%
|
| 2025-02-14 |
详情>>
业绩披露：
2025年一季报每股收益0.72美元,归母净利润1737.76万美元,同比去年增长255.46%
|
| 2025-02-10 |
股东大会：
将于2025-03-11召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees, Lawrence A. Kenyon, Julian Gangolli and Ralph H. “Randy” Thurman, to the Board of Directors as Class III Directors to hold office until the 2028 Annual Meeting of Stockholders.
2.To approve the potential issuance in excess of 19.99% of our outstanding common stock upon the conversion of a new convertible note at a conversion price per share that is less than the “minimum price” under Nasdaq Listing Rule 5635, if required pursuant to the terms of the convertible note.
3.To approve the amendment of Outlook Therapeutics, Inc.’s Restated Certificate of Incorporation, or the Restated Certificate, to increase the total number of shares of our common stock authorized for issuance from 60,000,000 shares to 260,000,000 shares.
4.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2025.
5.A non-binding advisory vote on the compensation of Outlook Therapeutics, Inc.’s named executive officers.
6.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2024-12-27 |
详情>>
业绩披露：
2024年年报每股收益-4.06美元,归母净利润-7536.67万美元,同比去年增长-27.78%
|
| 2024-09-26 |
详情>>
内部人交易：
KENYON LAWRENCE A股份增加5000.00股
|
| 2024-08-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-4.82美元,归母净利润-8105.8万美元,同比去年增长-76.24%
|
| 2024-08-14 |
财报披露：
美东时间 2024-08-14 盘前发布财报
|
| 2024-06-26 |
股东大会：
将于2024-08-12召开股东大会
会议内容 ▼▲
- 1.To approve the Outlook Therapeutics, Inc. 2024 Equity Incentive Plan;
2.To conduct any other business properly brought before the Special Meeting and any adjournment or postponement thereof.
|
| 2024-05-15 |
详情>>
业绩披露：
2024年中报每股收益-9.2美元,归母净利润-1.25亿美元,同比去年增长-395.59%
|
| 2024-03-14 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2024-02-14 |
详情>>
业绩披露：
2024年一季报每股收益-0.04美元,归母净利润-1117.82万美元,同比去年增长40.10%
|
| 2024-02-08 |
股东大会：
将于2024-03-07召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees, Gerd Auffarth, M.D., Julia A. Haller, M.D., Andong Huang and Lawrence A. Kenyon, to the Board of Directors as Class II Directors to hold office until the 2027 Annual Meeting of Stockholders.
2.To approve the potential issuance in excess of 19.99% of our outstanding common stock in a private placement of shares of common stock and accompanying warrants at a price per share that is less than the “minimum price” under Nasdaq Listing Rule 5635.
3.To approve the potential issuance in excess of 19.99% of our outstanding common stock upon the conversion of an outstanding convertible note at a conversion price per share that is less than the “minimum price” under Nasdaq Listing Rule 5635, if required pursuant to the terms of the convertible note.
4.To approve the amendment of Outlook Therapeutics, Inc.’s Amended and Restated Certificate of Incorporation, or the Restated Certificate, to increase the total number of shares of our common stock authorized for issuance from 425,000,000 shares to 1,200,000,000 shares.
5.To approve the amendment of the Restated Certificate to reflect new Delaware law provisions regarding officer exculpation.
6.To approve the amendment of the Restated Certificate to effect a reverse stock split of our issued and outstanding common stock, and a corresponding and proportionate reduction in the number of authorized shares of common stock, at a ratio of 1-for-10 to 1-for-30, to be determined in the sole discretion of the Board of Directors.
7.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2024.
8.A non-binding advisory vote on the compensation of Outlook Therapeutics, Inc.’s named executive officers.
9.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2023-12-22 |
详情>>
业绩披露：
2023年年报每股收益-0.24美元,归母净利润-5898.27万美元,同比去年增长10.70%
|
| 2023-02-15 |
股东大会：
将于2023-03-29召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees, Yezan Haddadin, Kurt J. Hilzinger and Faisal G. Sukhtian, to the Board of Directors as Class I Directors to hold office until the 2026 Annual Meeting of Stockholders.
2.To approve the amendment of Outlook Therapeutics, Inc.’s Amended and Restated Certificate of Incorporation to increase the total number of shares of our common stock authorized for issuance from 325,000,000 shares to 425,000,000 shares.
3.To approve the potential issuance in excess of 19.99% of our outstanding common stock upon the conversion of an outstanding convertible note at less than the “minimum price” under Nasdaq Listing Rule 5635, if required pursuant to the terms of the convertible note.
4.To ratify the selection by the Audit Committee of the Board of Directors of Kpmg Llp as our independent registered public accounting firm for the fiscal year ending September 30, 2023.
5.A non-binding advisory vote on the compensation of Outlook Therapeutics, Inc.’s named executive officers.
6.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2022-01-27 |
股东大会：
将于2022-03-23召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees, Ralph H. “Randy” Thurman, C. Russell Trenary III and Julian Gangolli to the Board of Directors as Class III Directors to hold office until the 2025 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2022.
3.A non-binding advisory vote on the compensation of Outlook Therapeutics Inc.’s named executive officers.
4.A non-binding advisory vote on the frequency of future advisory votes on the compensation of Outlook Therapeutics Inc.’s named executive officers.
5.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-02-22 |
股东大会：
将于2021-03-24召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees, Prof. Dr. Gerd Auffarth, Mr. Andong Huang and Mr. Lawrence Kenyon to the Board of Directors as Class II Directors to hold office until the 2024 Annual Meeting of Stockholders.
2.To approve the amendment of Outlook Therapeutics, Inc.’s Amended and Restated Certificate of Incorporation, as amended, or the Restated Certificate, to increase the total number of shares of our common stock authorized for issuance from 200,000,000 shares to 325,000,000 shares;
3.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2021.
4.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2020-08-18 |
股东大会：
将于2020-09-17召开股东大会
会议内容 ▼▲
- 1.To approve the amendment and restatement of the Company’s 2015 Equity Incentive Plan, or the 2015 Plan, as amended, to increase the total number of shares of the Company’s common stock issuable thereunder by 20,000,000 shares.
2.To conduct any other business properly brought before the Special Meeting and any adjournment or postponement thereof.
|
| 2020-02-14 |
股东大会：
将于2020-03-19召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees, Yezan Haddadin, Kurt J. Hilzinger and Faisal G. Sukhtian, to the Outlook Therapeutics Board of Directors as Class I Directors to hold office until the 2022 Annual Meeting of Stockholders.
2.To approve the amendment of the Certificate of Designation for the Series A-1 convertible preferred stock to reduce the effective conversion rate and expand the voting rights in proportion thereto (but capped at the “Minimum Price” under applicable Nasdaq rules).
3.To approve, as required by and in accordance with Nasdaq Listing Rule 5635(d), the issuance of more than 20% of our outstanding common stock at a price per share that is less than the “Minimum Price” pursuant to the terms of our outstanding voting Series A-1 convertible preferred stock, par value $0.01 per share.
4.To approve, as required by and in accordance with Nasdaq Listing Rules 5635(c) and 5635(d), the issuance of shares of our common stock to the principals of MTTR LLC, which include two of our executive officers.
5.To approve, as required by and in accordance with Nasdaq Listing Rule 5635(d), the issuance of more than 20% of our outstanding common stock at a price per share that is less than the “Minimum Price” upon conversion of our outstanding senior secured notes issued December 2019.
6.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2020.
7.To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|
| 2019-08-01 |
股东大会：
将于2019-09-12召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominee, Ralph H. “Randy” Thurman, to the Outlook Therapeutics Board of Directors as a Class III Director to hold office until the 2022 Annual Meeting of Stockholders.
2.To approve an amendment to our 2015 Equity Incentive Plan, as amended, or the 2015 Plan, to increase the share reserve.
3.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2019.
4.To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|
| 2019-03-18 |
详情>>
拆分方案：
每8.0000合并分成1.0000股
|
| 2018-08-17 |
股东大会：
将于2018-09-21召开股东大会
会议内容 ▼▲
- (1)To elect the Board’s nominees, Lawrence A. Kenyon, Joe Thomas and Joerg Windisch, Ph.D., to the Oncobiologics Board of Directors as Class II Directors to hold office until the 2021 Annual Meeting of Stockholders.
(2)To approve the amendment of Oncobiologics, Inc.’s Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of the Board of Directors, a reverse stock split of Oncobiologics, Inc.’s common stock at a reverse stock split ratio ranging from one-for-two (1:2) and one-for-ten (1:10), inclusive, with the effectiveness of such amendment and the abandonment of such amendment, to be determined by the Board of Directors on or prior to April 21, 2019.
(3)To approve an amendment to our 2015 Equity Incentive Plan, or the 2015 Plan, to increase the share reserve and make certain updating changes.
(4)To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2018.
(5)To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|
| 2017-09-29 |
股东大会：
将于2017-10-26召开股东大会
会议内容 ▼▲
- (1)To elect the Board’s nominees Albert D. Dyrness, Kurt J. Hilzinger and Faisal G. Sukhtian, to the Oncobiologics Board of Directors as Class I Directors to hold office until the 2020 Annual Meeting of Stockholders.
(2)To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2017.
(3)To approve, as required by and in accordance with NASDAQ Listing Rules 5635(b) and 5635(d), the issuance of securities that represent greater than 20% of our pre-transaction outstanding common stock, in a private placement, at a price less than the greater of book or market value, which securities consist of:
i.217,372 additional shares of our Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Preferred”), that are proposed to be issued pursuant to the Purchase Agreement, dated September 7, 2017 (the “Purchase Agreement”), between our company and GMS Tenshi Holdings Pte. Limited, as set forth in further detail in the accompanying proxy statement, which together with the 32,628 shares of Series A Preferred already to GMS Tenshi Holdings Pte. Limited issued pursuant to the Purchase Agreement, will represent 60.2% of the outstanding voting power, and will be convertible into an aggregate of 37,795,948 shares of our common stock, par value $0.01 per share;
ii.warrants to acquire 16,750,000 shares of our common stock issuable pursuant to the Purchase Agreement, as set forth in further detail in the accompanying proxy statement;
iii.1,500,000 shares of our Series B Non-Voting Convertible Preferred Stock, par value, $0.01 per share (“Series B Preferred”), which shares of Series B Preferred are convertible into an aggregate of 2,112,676 shares of our common stock and are issuable pursuant to the Purchase and Exchange Agreement, dated September 7, 2017, as set forth in further detail in the accompanying proxy statement;
along with any additional shares of our common stock that may be issuable pursuant to the terms of the Series A Preferred, warrants and Series B Preferred as set forth in further detail in the accompanying proxy statement; as well as the “change in control” of our company that will occur in connection with the issuance of the Series A Preferred and warrants as contemplated by the Purchase Agreement.
(4)To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|